Pharmaceutical

Lenvatinib mesylate by Eisai for Metastatic Biliary Tract Cancer: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Metastatic Biliary Tract Cancer.

Dec 24, 2023 - 18:00
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Metastatic Biliary Tract Cancer.
Read the original article

Tags:

Previous Article

STAT+: FDA approves AstraZeneca, Ionis treatment for rare nerve disease

Next Article

Mecbotamab vedotin by BioAtla for Breast Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Risk adjusted net present value: What is the current valuation of Moderna’s MRNA-3705?

Risk adjusted net present value: What is the current va...

Nov 18, 2023

The biotech updates you need to read today

The biotech updates you need to read today

Dec 19, 2023

STAT+: Pharmalittle: FDA to furlough one-fifth of staff if government shuts down; FDA cites ‘grossly deficient’ data for ALS drug

STAT+: Pharmalittle: FDA to furlough one-fifth of staff...

Sep 26, 2023